reversal agent

reversal agent

Anesthesiology Any drug used to reverse the effects of anesthetics, narcotics or potentially toxic agents Examples Antilirium, digibind, mestinon, narcan, neostigmine, protopam, pyridostigmin, romazicon, tensilon. See Induction agent.
References in periodicals archive ?
Prior to issuing an underwriting decision or making a rating decision, we encourage carriers to consider the reason for and intended use of an opioid reversal agent prescription.
PhaseBio Pharmaceuticals announced that results from the Phase 1 clinical trial of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, demonstrated that PB2452 provided immediate and sustained reversal of ticagrelor antiplatelet effects without report of drug-related serious adverse events.
Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
The transaction will enable AMAG to acquire global rights of ciraparantag, a next generation anticoagulant reversal agent, from Perosphere.
Shallow (TOFC=4; TOFR=0.1-0.4) and minimal (TOFC=4; TOFR >0.4 but <0.9) NMB should be reversed within 10 min after the application of the reversal agent because of safety issues (47).
Dabigatran, the first novel oral anticoagulant (NOAC) with a neutralizing reversal agent, ushered in a paradigm shift for the treatment of nonvalvular atrial fibrillation [1].
Idarucizumab (Praxbind) received FDA approval last October as a reversal agent for dabigatran.
(3) Debaene et al., observed TOF ratios <0.7 and <0.9 postoperatively in 16% and 45% of patients respectively in the PACU, in patients receiving a single intubating dose of indermediate acting muscle but no reversal agent at end of the procedure.
* The second major driver will be the approval and launch of the first antidotes for the NOACs, which will alleviate physician and patient concerns regarding a lack of a reversal agent in the event of uncontrolled bleeding, and will increase overall uptake.
(http://usatoday30.usatoday.com/news/health/story/2012-08-19/pradaxa-blood-thinner-lawsuit/57134628/1) A March 6, 2012 report by the Journal of Neurosurgery warns there is no reversal agent to stop fatal bleeding events in Pradaxa patients.
Whether sugammadex becomes the reversal agent of choice non-selectively will depend on its eventual market price, the outcome of future trials, and further experience with its use.